MANGALAM2026-07-012026-09-30MANGALAM2026-09-30MANGALAM2026-03-31MANGALAM2026-04-012026-09-30MANGALAM2026-07-012026-09-30in-capmkt:OtherExpenses1MemberMANGALAM2026-04-012026-09-30in-capmkt:OtherExpenses1MemberMANGALAM2026-09-30OtherNoncurrentAssetsDomain1MANGALAM2026-09-30OtherCurrentFinancialAssetsDomain1MANGALAM2026-09-30OtherCurrentAssetsDomain1MANGALAM2026-09-30OtherNoncurrentFinancialLiabilitiesDomain1MANGALAM2026-09-30OtherNoncurrentLiabilitiesDomain1MANGALAM2026-09-30OtherCurrentFinancialLiabilitiesDomain1MANGALAM2026-09-30OtherCurrentLiabilitiesDomain1MANGALAM2026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1MANGALAM2026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain1MANGALAM2026-06-30RelatedPartyTransactionDomain1MANGALAM2026-09-30RelatedPartyTransactionDomain1MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain2MANGALAM2026-06-30RelatedPartyTransactionDomain2MANGALAM2026-09-30RelatedPartyTransactionDomain2MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain3MANGALAM2026-06-30RelatedPartyTransactionDomain3MANGALAM2026-09-30RelatedPartyTransactionDomain3MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain4MANGALAM2026-06-30RelatedPartyTransactionDomain4MANGALAM2026-09-30RelatedPartyTransactionDomain4MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain5MANGALAM2026-06-30RelatedPartyTransactionDomain5MANGALAM2026-09-30RelatedPartyTransactionDomain5MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain6MANGALAM2026-06-30RelatedPartyTransactionDomain6MANGALAM2026-09-30RelatedPartyTransactionDomain6MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain7MANGALAM2026-06-30RelatedPartyTransactionDomain7MANGALAM2026-09-30RelatedPartyTransactionDomain7MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain8MANGALAM2026-06-30RelatedPartyTransactionDomain8MANGALAM2026-09-30RelatedPartyTransactionDomain8MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain9MANGALAM2026-06-30RelatedPartyTransactionDomain9MANGALAM2026-09-30RelatedPartyTransactionDomain9MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain10MANGALAM2026-06-30RelatedPartyTransactionDomain10MANGALAM2026-09-30RelatedPartyTransactionDomain10MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain11MANGALAM2026-06-30RelatedPartyTransactionDomain11MANGALAM2026-09-30RelatedPartyTransactionDomain11MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain12MANGALAM2026-06-30RelatedPartyTransactionDomain12MANGALAM2026-09-30RelatedPartyTransactionDomain12MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain13MANGALAM2026-06-30RelatedPartyTransactionDomain13MANGALAM2026-09-30RelatedPartyTransactionDomain13MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain14MANGALAM2026-06-30RelatedPartyTransactionDomain14MANGALAM2026-09-30RelatedPartyTransactionDomain14MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain15MANGALAM2026-06-30RelatedPartyTransactionDomain15MANGALAM2026-09-30RelatedPartyTransactionDomain15MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain16MANGALAM2026-06-30RelatedPartyTransactionDomain16MANGALAM2026-09-30RelatedPartyTransactionDomain16MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain17MANGALAM2026-06-30RelatedPartyTransactionDomain17MANGALAM2026-09-30RelatedPartyTransactionDomain17MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain18MANGALAM2026-06-30RelatedPartyTransactionDomain18MANGALAM2026-09-30RelatedPartyTransactionDomain18MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain19MANGALAM2026-06-30RelatedPartyTransactionDomain19MANGALAM2026-09-30RelatedPartyTransactionDomain19MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain20MANGALAM2026-06-30RelatedPartyTransactionDomain20MANGALAM2026-09-30RelatedPartyTransactionDomain20MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain21MANGALAM2026-06-30RelatedPartyTransactionDomain21MANGALAM2026-09-30RelatedPartyTransactionDomain21MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain22MANGALAM2026-06-30RelatedPartyTransactionDomain22MANGALAM2026-09-30RelatedPartyTransactionDomain22MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain23MANGALAM2026-06-30RelatedPartyTransactionDomain23MANGALAM2026-09-30RelatedPartyTransactionDomain23MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain24MANGALAM2026-06-30RelatedPartyTransactionDomain24MANGALAM2026-09-30RelatedPartyTransactionDomain24MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain25MANGALAM2026-06-30RelatedPartyTransactionDomain25MANGALAM2026-09-30RelatedPartyTransactionDomain25MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain26MANGALAM2026-06-30RelatedPartyTransactionDomain26MANGALAM2026-09-30RelatedPartyTransactionDomain26MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain27MANGALAM2026-06-30RelatedPartyTransactionDomain27MANGALAM2026-09-30RelatedPartyTransactionDomain27MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain28MANGALAM2026-06-30RelatedPartyTransactionDomain28MANGALAM2026-09-30RelatedPartyTransactionDomain28MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain29MANGALAM2026-06-30RelatedPartyTransactionDomain29MANGALAM2026-09-30RelatedPartyTransactionDomain29MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain30MANGALAM2026-06-30RelatedPartyTransactionDomain30MANGALAM2026-09-30RelatedPartyTransactionDomain30MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain31MANGALAM2026-06-30RelatedPartyTransactionDomain31MANGALAM2026-09-30RelatedPartyTransactionDomain31MANGALAM2026-07-012026-09-30RelatedPartyTransactionDomain32MANGALAM2026-06-30RelatedPartyTransactionDomain32MANGALAM2026-09-30RelatedPartyTransactionDomain32MANGALAM2026-07-012026-09-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532637MANGALAMNOTLISTEDINE584F01014MANGALAM DRUGS AND ORGANICS LIMITEDMain BoardEquity2026-04-012027-03-312026-11-052026-10-29INRLakhsQuarterlySecond quarterSingle segmentManufacture of Bulk Drugs2026-11-0514:30:002026-11-0517:30:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2026-11-05https://www.mangalamdrugs.com/wp-content/uploads/2022/08/Policy-on-Related-Party-Transaction_MDOL.pdffalsetrue2026-07-012026-09-30UnauditedStandalone79392400016820007956060004677300002700000064187000925870003887300040241000154909000885527000-899210000-899210000-17828000-178280000-720930000000-72093000-1415000-735080001582820001582.82-4.55-4.5500-4.55-4.551. The unaudited standalone financial results for the Quarter and Half year ended September 30, 2026 have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the Companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter. <br /> <br /> 2. The above unaudited standalone financial results of the Company for the Quarter and Half year ended September 30, 2026 have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company (Mangalam Drugs and Organics Limited) at their meeting held on November 5, 2026. Statutory auditors have carried Limited Review for the quarter and half year ended on that date. <br /> <br /> 3. The Company's business activity falls within a single reportable Business Segment Viz. “Manufacturing of Bulk Drugs”. <br /> <br /> 4. The figures for the quarter ended 30th September, 2026 are the balancing figures between the figures in respect of half year ended 30th September, 2026 and the unaudited published figures for the quarter ended 30th June 2026. <br /> <br /> 5. The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("Second Transferor Company") with Mangalam Drugs and Organics Limited ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. As on the date the scheme of merger is yet to be heard by Hon’ble National Company Law Tribunal. <br /> <br /> 6. During the quarter, the Company has recognized deferred tax asset on tax losses based on the projection available with the Company as on date which will be reviewed at the end of the year. <br /> <br /> 7. Other Expenses <br /> Rs in Lakhs <br /> Particulars Quarter Ended Half Year Ended Year Ended <br /> 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 <br /> Unaudited Unaudited Unaudited Unaudited Unaudited Audited <br /> Power and Fuel Expenses 567.81 568.58 437.32 1,136.39 883.62 1,828.81 <br /> <br /> 8. The cash credit accounts of the Company with Bank of Maharashtra and Bank of Baroda, members of the consortium led by State Bank of India, have exceeded the sanctioned drawing power since 17 October 2025 and 20 October 2025 respectively, mainly on devolvement of letters of credit, and have been classified as Non-Performing Assets with effect from 17th January 2026 and 19th January 2026 respectively. The facilities with State Bank of India continue to be standard. As at 30 September 2026, the outstanding to these two banks was Rs 5,556.52 lakhs, on which interest has been fully provided for, and the entire amount has been classified as current. Bank of Baroda has issued a demand notice dated 23 September 2026 under Section 13(2) of the SARFAESI Act, 2002 for Rs 2,671.57 lakhs. The Company is in the process of replying to the notice and is in discussion with the lenders to resolve the debt. <br /> These conditions, together with current liabilities exceeding current assets by Rs 4,521.21 lakhs as at 30 September 2026, indicate a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern. Considering its net worth of Rs 8,827.60 lakhs, the continuing operations of both manufacturing units, the standard classification of the account by the lead bank and the ongoing discussions with the lenders to resolve the debt, the Board considers it appropriate to prepare the financial results on a going concern basis. <br /> <br /> 9. The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods classification.2026-04-012026-09-30UnauditedStandalone136511700027990001367916000803675000270000005976500018082400075626000801430002974130001524446000-1565300000-1565300000-8901000-89010000-1476290000000-147629000-2831000-1504600001582820001582.82-9.33-9.3300-9.33-9.33Other Expenses154909000Other Expenses29741300010376940000003710760004735400000327000003270000213500014585860009627220000328961000805600004940003200100036951200001252800001457514000002916100000158282000724478000882760000882760000519200000006194000581140000421590000234320001237050008284940001092670005889450006982120007646100016031670002909750001549300000190963500020333400002916100000Other non-current assets2135000Other current financial assets32001000Other current assets125280000Other non-current financial liabilities6194000Other non-current liabilities23432000Other current financial liabilities76461000Other current liabilities2909750007562600065014000740100000-38295000710000000965300001202980003315000801430000184600000000001673000000-3783000039021000023368000000000233680000000000001227000178260000000000000000000000018000-16581000000000000140143000007562600000-21576900013300000133000067250008055000Other comprehensive income [Abstract]-1415000-1415000Other comprehensive income [Abstract]-2831000-28310000000-1415000-2831000Mangalam Drugs and Organics Limited******Raga Organics Private Limited******Private Company in which a Director or Manager or his relative is a member or DirectorAny other transactionRent Received100000NA300060003000Mangalam Drugs and Organics Limited******Mangalam Laboratories Private Limited******Wholly owned subsidiaryAdvance300000000NA180641000178083000180641000Mangalam Drugs and Organics Limited******Shri J.B Pharma Private Limited******Private Company in which a Director or Manager or his relative is a member or DirectorAny other transactionRent Received100000NA180003600018000Mangalam Drugs and Organics Limited******Shri J.B Pharma Private Limited******Private Company in which a Director or Manager or his relative is a member or DirectorAny other transactionRent Deposit100000NA500050005000Mangalam Drugs and Organics Limited******Shri J.B Pharma Private Limited******Private Company in which a Director or Manager or his relative is a member or DirectorPurchase of goods or services100000000NA0407700000Mangalam Drugs and Organics Limited******Shri J.B Pharma Private Limited******Private Company in which a Director or Manager or his relative is a member or DirectorSale of goods or services100000000NA000Mangalam Drugs and Organics Limited******Mangalam Laboratories Private Limited******Wholly owned subsidiaryAny other transactionCommission paid on sales4000000NA030450000Mangalam Drugs and Organics Limited******Rakesh Milwani******Non-Executive DirectorAny other transactionSitting fees100000NA100002000010000Mangalam Drugs and Organics Limited******Mrs. Nidhi Mundada******Non-Executive DirectorAny other transactionSitting fees100000NA160004800016000Mangalam Drugs and Organics Limited******Mr. Rukmesh Dhandhania******Non-Executive DirectorAny other transactionSitting fees100000NA0340000Mangalam Drugs and Organics Limited******Mr. Praveen Saxena******Non-Executive DirectorAny other transactionSitting fees100000NA140003200014000Mangalam Drugs and Organics Limited******Ms. Anauradha Pandey******Company SecretaryAny other transactionSalary2000000NA012790000Mangalam Drugs and Organics Limited******Govardhan M. Dhoot******Chairman & Managing Director (KMP)Remuneration5000000NA100000020170001000000Mangalam Drugs and Organics Limited******Brijmohan M. Dhoot******Executive DirectorRemuneration1000000NA300000617000300000Mangalam Drugs and Organics Limited******Mr. Ajay Samant******Chief Financial OfficerAny other transactionSalary3000000NA025230000Mangalam Drugs and Organics Limited******Mrs. Rekha G. Dhoot******Promoter groupAny other transactionSalary3000000NA146000029420001460000Mangalam Drugs and Organics Limited******Mrs. Jyoti B. Dhoot******Promoter groupAny other transactionSalary3000000NA146000029420001460000Mangalam Drugs and Organics Limited******Ms. Shweta G. Dhoot******Promoter groupAny other transactionSalary1000000NA431000883000431000Mangalam Drugs and Organics Limited******Mrs. Krishnapriya Nawal******Relative of KMPAny other transactionSalary3000000NA012530000Mangalam Drugs and Organics Limited******Mrs. Radhika A Dhoot******Promoter groupAny other transactionSalary2000000NA7320001484000732000Mangalam Drugs and Organics Limited******Mrs. Smita A. Dhoot******Promoter groupAny other transactionSalary2000000NA7320001484000732000Mangalam Drugs and Organics Limited******Mr. Yaduraj A. Dhoot******Relative of KMPAny other transactionSalary5000000NA204600041130002046000Mangalam Drugs and Organics Limited******Ms. Mahima A. Dhoot******Relative of KMPAny other transactionSalary5000000NA204600041130002046000Mangalam Drugs and Organics Limited******Ms. Kripa Saraf******Relative of promoter groupAny other transactionLegal / Professional /Tech.fees2000000NA08480000Mangalam Drugs and Organics Limited******Mr. Jeevan Dalvi******Chief Financial Office from 06-02-2026Any other transactionSalary2000000NA3650001109000365000Mangalam Drugs and Organics Limited******Anuradha Pandey******Company SecretaryAny other transactionTermination Benefit100000NA0620000Mangalam Drugs and Organics Limited******Shweta Patel******Company SecretaryAny other transactionSalary1500000NA5050000505000Mangalam Drugs and Organics Limited******Shweta Patel******Company SecretaryAny other transactionTermination Benefit100000NA26000026000Mangalam Drugs and Organics Limited******Mangalam Laboratories Private Limited******Wholly owned subsidiaryAny other transactionrent paid500000NA210000420000210000Mangalam Drugs and Organics Limited******Jeevan Dalvi******Chief Financial Officer from 06-02-2026Any other transactionTermination Benefit100000NA130004000013000Mangalam Drugs and Organics Limited******Shri J.B Pharma Private Limited******Private Company in which a Director or Manager or his relative is a member or DirectorAny other transactionRent Deposit100000NA050000Mangalam Drugs and Organics Limited******Mangalam Laboratories Private Limited******Wholly owned subsidiaryAny other transactionConsultancy Fees Paid250000000NA300000003000000195033000UnauditedtrueM/s SN Nanda and Companytrue2029-03-31155727000155727000000